Primary headache disorders (including migraine, cluster headache, cervicogenic headache, occipital neuralgia and other primary headaches) are common and disabling; migraine affects about 15% of the population and transformed migraine is chronic (>15 days/month), while cluster headache can become chronic in 10–20% of patients and may be refractory to medical treatment. Cervicogenic headache typically begins in the suboccipital region with pain referred to trigeminal sensory fields and many ablative surgical procedures have inconsistent effects and carry serious complication risks.
Neurostimulation approaches for intractable primary headache disorders emerged in the early 2000s and build on prior spinal cord stimulation work. Two broad types are described: peripheral approaches targeting occipital nerve branches (Occipital Nerve Stimulation, ONS) and central approaches using Deep Brain Stimulation (DBS) such as posterior hypothalamic stimulation for chronic cluster headache.
ONS implantation is typically a three‑phase surgical procedure: phase 1—subcutaneous bilateral electrode implantation over the greater occipital nerve; phase 2—external stimulator testing with awake patient feedback as amplitude is increased (0 to ~4 V) to confirm paresthesia radiating ≥4 cm cephalad from skull base; phase 3—implantation of the pulse generator (pectoral/abdominal/gluteal) and connection via tunneled leads. Reported complications include lead migration, infection, localized pain, muscle spasm, and loss of effect.
DBS involves MRI‑guided stereotactic placement of one or more electrodes (e.g., posterior hypothalamus, thalamus, globus pallidus, subthalamic nucleus), often initially tested with temporary transcutaneous cables before permanent implantation and subsequent programmable noninvasive adjustments. DBS requires highly experienced neurosurgeons and carries risks including intracerebral hemorrhage and possible mortality; preoperative neuroimaging is required to exclude conditions increasing hemorrhagic risk. Neither ONS nor DBS are FDA‑approved for the treatment or prevention of primary headaches.